Current Management Strategies for Ovarian Cancer

Aletti, Giovanni D.; Gallenberg, Mary M.; Cliby, William A.; Jatoi, Aminah; Hartmann, Lynn C.
June 2007
Mayo Clinic Proceedings;Jun2007, Vol. 82 Issue 6, p751
Academic Journal
Epithelial ovarian cancer originates in the layer of cells that covers the surface of the ovaries. The disease spreads readily throughout the peritoneal cavity and to the lymphatics, often before causing symptoms. Of the cancers unique to women, ovarian cancer has the highest mortality rate. Most women are diagnosed as having advanced stage disease, and efforts to develop new screening approaches for ovarian cancer are a high priority. Optimal treatment of ovarian cancer begins with optimal cytoreductive surgery followed by combination chemotherapy. Ovarian cancer, even in advanced stages, is sensitive to a variety of chemotherapeutics. Although improved chemotherapy has increased 5-year survival rates, overall survival gains have been limited because of our inability to eradicate all disease. Technologic advances that allow us to examine the molecular machinery that drives ovarian cancer cells have helped to identify numerous therapeutic targets within these cells. In this review, we provide an overview of ovarian cancer with particular emphasis on recent advances in operative management and systemic therapies.


Related Articles

  • Advanced Ovarian Cancer: Long-Term Results of Treatment with Intensive Cisplatin-Based Chemotherapy of Brief Duration. Hainsworth, John D.; Grosh, William W.; Burnett, Lonnie S.; Jones, Howard W.; Wolff, Steven N.; Greco, F. Anthony // Annals of Internal Medicine;Feb88, Vol. 108 Issue 2, p165 

    Determines the efficacy of a course of combination chemotherapy with hexamethylmelamine, cyclophosphamide, doxorubicin and cisplatin in the treatment of advanced ovarian carcinoma. Characteristics of patients with advanced ovarian cancer; Importance of combination therapy in the treatment of...

  • P-0212 PREOPERATIVE CHEMOTHERAPY IN PATIENTS WITH COLORECTAL LIVER METASTASIS: EXPERIENCE OF GROUP OF GASTROINTESTINAL TUMOURS OF RIMINI. Emiliano, Tamburini; Luigi, Veneroni; Britt, Rudnas; Luisa, Nicoletti Stefania Vittoria; Marco, Palini Gian; Fabrizio, Drudi; Filippo, Paratore; Manuela, Fantini; Laura, Della Chiesa; Giacomo, Crescentini; Gabriele, Donati; Enrico, Cavagna; GianFranco, Francioni; Davide, Tassinari // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii79 

    No abstract available.

  • Single-agent chemo for ovarian cancer: just as effective and less toxic.  // Contemporary OB/GYN;Jan2003, Vol. 48 Issue 1, p29 

    Discusses research being done on the use of single-agent chemotherapy for ovarian cancer. Reference to a study by the International Collaborative Ovarian Neoplasm Group published in a 2002 issue of "Lancet"; Comparison of the effectiveness of single-agent therapy and paclitaxel plus carboplatin...

  • Tumour immunology: Cracking the combination. Bordon, Yvonne // Nature Reviews Immunology;Jul2013, Vol. 13 Issue 7, p469 

    The article discusses the studies that describe the potential strategies for combining immunotherapies for cancer treatment. The researchers have observed that tumors or cancer cells can evade the immune system by targeting the regulatory networks that protect healthy cells from immune-mediated...

  • Perspective: Combined forces. Sawyers, Charles L. // Nature;6/27/2013 Supplement, Vol. 498 Issue 7455, pS7 

    The author discusses various aspects of prescribing combination drug therapies to cancer patients which leads to development of drug resistance in cancer cells. According to the author, the clinical practice in which the clinicians changes the drugs in case if patients fails to show positive...

  • Can we conquer cancer in the twenty-first century? Freireich, Emil J. // Cancer Chemotherapy & Pharmacology. Supplement;Jul2001, Vol. 48, pS4 

    The twentieth century recorded the greatest advance in the control of human disease. From the beginning of recorded time, the human life-span changed little until the twentieth century. In the USA, it increased from 47.3 years in 1900 to 76.4 years in 2000. The answer to the question of "Can we...

  • Informatics of Drug Synergism in Naturally Occurring Anticancer Agents. Ghavami, Ghazaleh; Kazemali, Mohammad R.; Sardari, Soroush // Recent Patents on Anti-Cancer Drug Discovery;Jan2011, Vol. 6 Issue 1, p26 

    Cancer is a multi-factorial disease resulting in uncontrolled division of body cells, with difficult and complex suppression. The main treatment strategy for this disease depends on killing of tumor cells that usually exist in the proximity of normal body cells. During the course of treatment,...

  • A genomic approach to predict synergistic combinations for breast cancer treatment. Soldi, R; Cohen, A L; Cheng, L; Sun, Y; Moos, P J; Bild, A H // Pharmacogenomics Journal;Feb2013, Vol. 13 Issue 1, p94 

    We leverage genomic and biochemical data to identify synergistic drug regimens for breast cancer. In order to study the mechanism of the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) in breast cancer, we generated and validated genomic...

  • Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. Ioannou, Nikolaos; Seddon, Alan M.; Dalgleish, Angus; Mackintosh, David; Modjtahedi, Helmout // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Aberrant expression and activation of the IGF-IR have been reported in a variety of human cancers and have been associated with resistance to HER targeted therapy. In this study, we investigated the effect of simultaneous targeting of IGF-IR and HER (erbB) family, with NVP-AEW541 and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics